|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2010-6-15
|
|
pubmed:abstractText |
New data support use of levodopa pharmacotherapy with behavioral contingency management (CM) as one efficacious combination in cocaine dependence disorder treatment. A potential mechanism of the combined treatment effects may be related to dopamine-induced enhancement of the saliency of contingently delivered reinforcers. Evidence to support this mechanism was sought by evaluating levodopa-enhancing effects across distinct CM conditions that varied in behavioral targets. A total of 136 treatment-seeking, cocaine dependent subjects participated in this 12-week, randomized, placebo-controlled trial of levodopa (vs. placebo) administered in combination with one of three behavioral CM conditions. In the CM-URINE condition, subjects received cash-valued vouchers contingent on cocaine-negative urine toxicology results. In the CM-ATTEND condition, the same voucher schedule was contingent on attending thrice weekly clinic visits. In the CM-MEDICATION condition, the same voucher schedule was contingent on Medication Event Monitoring Systems- and riboflavin-based evidence of pill-taking behavior. Primary outcomes associated with each CM target behavior were analyzed using generalized linear mixed models for repeated outcomes. CM responding in the CM-ATTEND and CM-MEDICATION conditions showed orderly effects, with each condition producing corresponding changes in targeted behaviors, regardless of medication condition. In contrast, CM responding in the CM-URINE condition was moderated by medication, with levodopa-treated subjects more likely to submit cocaine-negative urines. These findings specify the optimal target behavior for CM when used in combination with levodopa pharmacotherapy.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-10453799,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-10669055,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-11137278,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-11550730,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-12369474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-12665084,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-12750391,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-12757969,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-1334156,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-15050670,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-15098002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-15276217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-15561476,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-16366768,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-16445548,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-17034434,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-17056206,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-17613963,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-17613964,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-18031424,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-18085914,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-18164144,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-9283509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/20545388-9608348
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1936-2293
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
238-44
|
|
pubmed:dateRevised |
2011-9-26
|
|
pubmed:meshHeading |
pubmed-meshheading:20545388-Adult,
pubmed-meshheading:20545388-Behavior Therapy,
pubmed-meshheading:20545388-Carbidopa,
pubmed-meshheading:20545388-Cocaine,
pubmed-meshheading:20545388-Cocaine-Related Disorders,
pubmed-meshheading:20545388-Dopamine Agents,
pubmed-meshheading:20545388-Female,
pubmed-meshheading:20545388-Humans,
pubmed-meshheading:20545388-Levodopa,
pubmed-meshheading:20545388-Male,
pubmed-meshheading:20545388-Medication Adherence,
pubmed-meshheading:20545388-Middle Aged,
pubmed-meshheading:20545388-Proportional Hazards Models,
pubmed-meshheading:20545388-Reinforcement (Psychology),
pubmed-meshheading:20545388-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Contingency management and levodopa-carbidopa for cocaine treatment: a comparison of three behavioral targets.
|
|
pubmed:affiliation |
Department of Psychiatry and Behavioral Sciences, University of Texas-Houston, Houston, TX, USA. joy.m.schmitz@uth.tmc.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Research Support, N.I.H., Extramural
|
